Citations

Clear

3042 citation(s) found for "Kumar, S".

Concurrent TERT promoter C228T and C250T mutations in diffuse gliomas: Rare occurrence of intratumoral heterogeneity
Koleilat, Alaa , Hmada, Youssef Al , Milosevic, Dragana , Zheng, Gang , Lopes, Maria Beatriz, Ida, Cristiane M. , Ida, Cristiane M , Kumar, Vijay , Lopes, M. Beatriz S.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | October 9, 2023 | Volume: 82 | Issue: 12 | Pages: 1044-1047

10.1093/jnen/nlad081 | PMID 37812785 Get It

FRI048 Cardiometabolic Risk Markers In Children With Obesity And Variants In MC4R Pathway Related Genes
Kumar, Seema , Hentz, Roland, Salama, Mostafa, Vairo, Filippo Pinto e

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.059 Get It

Abstract Disclosure: M. Salama: None. S. Kumar: None. F. Pinto e Vairo: None. R. Hentz: None. Objective: The association between disrupted melanocortin 4 receptor (MC4R) pathway function and childhood obesity is well established. Several variants in MC4R pathway related genes have been implicated to influence cardiometabolic parameters including lipid metabolism and glucose homeostasis. We compared the cardiometabolic risk markers in children with obesity and MC4R related clinically reported genetic variants relative to children with obesity and no MC4R related genetic variants. Methods: This was a retrospective case-control study conducted by chart review of children (age <18 years) with obesity who underwent a multi-gene panel testing for monogenic obesity between February 2020 and November 2022. Children were divided into two groups according to their genetic test results: The first group was of children with clinically reported variants (pathogenic, likely pathogenic, risk allele or variant of uncertain significance) within the MC4R pathway), and the second group was of children with no reported variants in the MC4R pathway (negative genetic testing or variants in non-MC4R related genes). Data on systolic and diastolic blood pressure percentiles, fasting lipid panel, fasting blood glucose, hemoglobin A1c and ALT were extracted. Tests for group differences were performed using the independent two-sample t-test, Wilcoxon rank-sum test, Chi-Square test, or Fisher’s exact test as appropriate for each variable type and test assumptions. Results: Data on a total of 91 children were reviewed. Mean age at testing was 11 years (SD: 4) and mean peak BMI% of the 95th percentile was 158 (SD: 28). 36 patients had clinically reported variants in the MC4R pathway, and 55 patients had no reported MC4R related variants. The blood pressure percentiles, fasting glucose, hemoglobin A1C, total cholesterol, high density lipoprotein cholesterol and low-density lipoprotein cholesterol were not different between both groups. Conclusion: In this pilot study, among children with obesity, variants in the MC4R pathway related genes were not associated with cardiometabolic risk markers. Larger studies are warranted to assess the correlation between MC4R pathway genes and cardiometabolic risk. Presentation: Friday, June 16, 2023
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG‐ACRIN Cancer Research Group trials
Walter, Angela Wangari , Lee, Ju‐Whei, Gareen, Ilana F. , Herman, B. , Kircher, Sheetal Mehta , Carlos, Ruth C. , Kumar, Shaji , Saba, Nabil F. , Fenske, Timothy S. , Neal, Joel W. , Hodi, Frank S., Kyriakopoulos, Christos E. , Tempany, Clare M. , Shanafelt, Tait D. , Kircher, Sheetal M , Carlos, Ruth , Kumar, Shaji K , Saba, Nabil F , Neal, Joel W , Wagner, Lynne , Ostroff, Jamie S , Park, Elyse R , Shanafelt, Tait D , Lee, Ju‐Whei , Streck, Joanna M. , Mayer, Ingrid A. , Atkins, Michael B. , Wagner, Lynne I. , Land, Stephanie R

Mayo Clinic

Cancer | October 5, 2023 | Volume: 130 | Issue: 3 | Pages: 439-452

10.1002/cncr.35039 | PMID 37795845 Get It

AbstractBackgroundTobacco use is associated with adverse outcomes among patients diagnosed with cancer. Socioeconomic determinants influence access and utilization of tobacco treatment; little is known about the relationship between neighborhood socioeconomic disadvantage (NSD) and tobacco assessment, assistance, and cessation among patients diagnosed with cancer.MethodsA modified Cancer Patient Tobacco Use Questionnaire (C‐TUQ) was administered to patients enrolled in nine ECOG‐ACRIN clinical trials. We examined associations of NSD with (1) smoking status, (2) receiving tobacco cessation assessment and support, and (3) cessation behaviors. NSD was classified by tertiles of the Area Deprivation Index. Associations between NSD and tobacco variables were evaluated using logistic regression.ResultsA total of 740 patients completing the C‐TUQ were 70% male, 94% White, 3% Hispanic, mean age 58.8 years. Cancer diagnoses included leukemia 263 (36%), lymphoma 141 (19%), prostate 131 (18%), breast 79 (11%), melanoma 69 (9%), myeloma 53 (7%), and head and neck 4 (0.5%). A total of 402 (54%) never smoked, 257 (35%) had formerly smoked, and 81 (11%) were currently smoking. Patients in high disadvantaged neighborhoods were approximately four times more likely to report current smoking (odds ratio [OR], 3.57; 95% CI, 1.69–7.54; p = .0009), and more likely to report being asked about smoking (OR, 4.24; 95% CI, 1.64–10.98; p = .0029), but less likely to report receiving counseling (OR, 0.11; 95% CI, 0.02–0.58; p = .0086) versus those in the least disadvantaged neighborhoods.ConclusionsGreater neighborhood socioeconomic disadvantage was associated with smoking but less cessation support. Increased cessation support in cancer care is needed, particularly for patients from disadvantaged neighborhoods.
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Lee, Yoo Jin , Li, Dalin , Debbas, Philip , Hampton, Melissa, Ebinger, Joseph E. , Chiorean, Michael , Lum, Donald , Damas, Oriana M. , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Mengesha, Emebet , Cheng, Susan , McGovern, Dermot , Group, CORALE-IBD Study, Botwin, Gregory J., White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Mayo Clinic

Inflammatory Bowel Diseases | September 29, 2023 | Volume: 30 | Issue: 8 | Pages: 1430-1434

10.1093/ibd/izad198 | PMID 37773982 Get It

Post Living Donor Liver Transplantation Small-for-size Syndrome: Definitions, Timelines, Biochemical, and Clinical Factors for Diagnosis: Guidelines From the ILTS-iLDLT-LTSI Consensus Conference
Kow, Alfred Wei Chieh , Martin, Eléonora De , Soejima, Yuji , Watt, Kymberly D. , Xia, Qiang , Saraf, Neeraj, Kamel, Refaat, Srinvasan, Parthi, Elsabbagh, Ahmed M. , Pamecha, Vinayendra, Palaniappan, Kumar , Mas, Valeria R. , Tokat, Yaman , Asthana, Sonal , Cherukuru, Ramkiran , Egawa, Hiroto , Lerut, Jan , Bröering, Dieter C. , Berenguer, Marina , Cattral, Mark S. , Clavien, Pierre‐Alain , Chen, Chao‐Long , Shah, Samir , Zhu, Zhi‐Jun , Emond, Jean C. , Ascher, Nancy L. , Rela, Mohamed , Kim, Dong‐Sik , Ikegami, Toru , Group, On behalf of the ILTS-iLDLT-LTSI SFSS Working, Watt, Kymberly, Berenguer, Marina , Liu, Jiang , Patel, Madhukar S. , Reddy, Mettu Srinivas , Syn, Nicholas L. X. , Nasralla, David , McKenna, Greg J. , Palaniappan, Kumar , Asthana, Sonal , Rammohan, Ashwin , Bhangui, Prashant , Group, On behalf of the ILTS-iLDLT-LTSI SFSS Working

Mayo Clinic

Transplantation | September 26, 2023 | Volume: 107 | Issue: 10 | Pages: 2226-2237

10.1097/tp.0000000000004770 | PMID 37749812 Get It

Background. When a partial liver graft is unable to meet the demands of the recipient, a clinical phenomenon, small-for-size syndrome (SFSS), may ensue. Clear definition, diagnosis, and management are needed to optimize transplant outcomes. Methods. A Consensus Scientific committee (106 members from 21 countries) performed an extensive literature review on specific aspects of SFSS, recommendations underwent blinded review by an independent panel, and discussion/voting on the recommendations occurred at the Consensus Conference. Results. The ideal graft-to-recipient weight ratio of ≥0.8% (or graft volume standard liver volume ratio of ≥40%) is recommended. It is also recommended to measure portal pressure or portal blood flow during living donor liver transplantation and maintain a postreperfusion portal pressure of <15 mm Hg and/or portal blood flow of <250 mL/min/100 g graft weight to optimize outcomes. The typical time point to diagnose SFSS is the postoperative day 7 to facilitate treatment and intervention. An objective 3-grade stratification of severity for protocolized management of SFSS is proposed. Conclusions. The proposed grading system based on clinical and biochemical factors will help clinicians in the early identification of patients at risk of developing SFSS and institute timely therapeutic measures. The validity of this newly created grading system should be evaluated in future prospective studies.
Anesthesia and Critical Care for the Prediction and Prevention for Small-for-size Syndrome: Guidelines from the ILTS-iLDLT-LTSI Consensus Conference
Rajakumar, Akila , Shingina, Alexandra , Yoon, Uzung , Patel, Dhupal , Spiro, Michael , Bhangui, Pooja , Sun, Li-Ying, Humar, Abhinav , Findlay, James Y. , Saigal, Sanjiv , Rodríguez-Dávalos, Manuel I. , Kumar, Lakshmi , Kumaran, Vinay , Agarwal, Shaleen , Egawa, Hiroto , Lerut, Jan , Bröering, Dieter C. , Berenguer, Marina , Cattral, Mark S. , Clavien, Pierre‐Alain , Chen, Chao‐Long , Shah, Samir, Zhu, Zhi‐Jun , Ascher, Nancy L. , Emond, Jean C. , Rela, Mohamed , Findlay, James, Berenguer, Marina , Chadha, Ryan , Sakai, Tetsuro , Bezinover, Dmitri , Singh, Shweta A , Yi, Nam‐Joon , Berlakovich, Gabriela , Bhangui, Prashant , Rammohan, Ashwin

Mayo Clinic

Transplantation | September 26, 2023 | Volume: 107 | Issue: 10 | Pages: 2216-2225

10.1097/tp.0000000000004803 | PMID 37749811 Get It

Background. During the perioperative period of living donor liver transplantation, anesthesiologists and intensivists may encounter patients in receipt of small grafts that puts them at risk of developing small for size syndrome (SFSS). Methods. A scientific committee (106 members from 21 countries) performed an extensive literature review on aspects of SFSS with proposed recommendations. Recommendations underwent a blinded review by an independent expert panel and discussion/voting on the recommendations occurred at a consensus conference organized by the International Liver Transplantation Society, International Living Donor Liver Transplantation Group, and Liver Transplantation Society of India. Results. It was determined that centers with experience in living donor liver transplantation should utilize potential small for size grafts. Higher risk recipients with sarcopenia, cardiopulmonary, and renal dysfunction should receive small for size grafts with caution. In the intraoperative phase, a restrictive fluid strategy should be considered along with routine use of cardiac output monitoring, as well as use of pharmacologic portal flow modulation when appropriate. Postoperatively, these patients can be considered for enhanced recovery and should receive proactive monitoring for SFSS, nutrition optimization, infection prevention, and consideration for early renal replacement therapy for avoidance of graft congestion. Conclusions. Our recommendations provide a framework for the optimal anesthetic and critical care management in the perioperative period for patients with grafts that put them at risk of developing SFSS. There is a significant limitation in the level of evidence for most recommendations. This statement aims to provide guidance for future research in the perioperative management of SFSS.
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate‐to‐Severe Osteoarthritis or Ad
Goodman, Susan M. , Yates, Adolph J. , Baker, Joshua F. , Bass, Phyllis, Bekele, Delamo I. , Dass, Danielle, Jevsevar, David S. , Suleiman, Linda I. , Wolfstadt, Jesse , Bartosiak, Kimberly , Cohen‐Rosenblum, Anna , Courtney, P. Maxwell , Ghosh, Nilasha , Mehta, Bella , Rana, Adam J. , Sullivan, Nancy , Turgunbaev, Marat, Wysham, Katherine D. , Yip, Kevin , Yue, Linda, Zywiel, Michael G. , Russell, Linda , Turner, Amy S. , Goodman, Susan M , Baker, Joshua F , Bekele, Delamo , Ghomrawi, Hassan M K , Kwoh, Chian Kent , Bedard, Nicholas A. , Ghosh, Nilasha , King, Lauren K , Meara, Alexa Simon , Wysham, Katherine D , Turner, Amy S , Hannon, Charles P. , Austin, Matthew S. , Guyatt, Gordon , Aggarwal, Vinay Kumar , Ghomrawi, Hassan , Lajam, Claudette M. , Meng, Charis F. , Moreland, Larry W. , Blevins, Jason L. , Fernandez‐Ruiz, Ruth , Gausden, Elizabeth B. , Mirza, Reza Donald , Singh, Jasvinder A.

Mayo Clinic

Arthritis & Rheumatology | September 25, 2023 | Volume: 75 | Issue: 11 | Pages: 1877-1888

10.1002/art.42630 | PMID 37746897 Get It

ObjectiveTo develop evidence‐based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient‐important outcomes including, but not limited to, pain, function, infection, hospitalization, and death at 1 year for patients with symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis of the hip or knee who have previously attempted nonoperative therapy, and for whom nonoperative therapy was ineffective, and who have chosen to undergo elective hip or knee arthroplasty (collectively referred to as TJA).MethodsWe developed 13 clinically relevant population, intervention, comparator, outcomes (PICO) questions. After a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of evidence (high, moderate, low, or very low), and evidence tables were created. A Voting Panel, including 13 physicians and patients, discussed the PICO questions until consensus was achieved on the direction (for/against) and strength (strong/conditional) of the recommendations.ResultsThe panel conditionally recommended against delaying TJA to pursue additional nonoperative treatment including physical therapy, nonsteroidal antiinflammatory drugs, ambulatory aids, and intraarticular injections. It conditionally recommended delaying TJA for nicotine reduction or cessation. The panel conditionally recommended delay for better glycemic control for patients who have diabetes mellitus, although no specific measure or level was identified. There was consensus that obesity by itself was not a reason for delay, but that weight loss should be strongly encouraged, and the increase in operative risk should be discussed. The panel conditionally recommended against delay in patients who have severe deformity or bone loss, or in patients who have a neuropathic joint. Evidence for all recommendations was graded as low or very low quality.ConclusionThis guideline provides evidence‐based recommendations regarding the optimal timing of TJA in patients who have symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy was ineffective to improve patient‐important outcomes, including pain, function, infection, hospitalization, and death at 1 year. We acknowledge that the evidence is of low quality primarily due to indirectness and hope future research will allow for further refinement of the recommendations.
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate‐to‐Severe Osteoarthritis or Ad
Goodman, Susan M. , Yates, Adolph J. , Baker, Joshua F. , Bass, Phyllis, Bekele, Delamo I. , Dass, Danielle, Jevsevar, David S. , Suleiman, Linda I. , Wolfstadt, Jesse , Bartosiak, Kimberly , Cohen‐Rosenblum, Anna , Courtney, P. Maxwell , Ghosh, Nilasha , Mehta, Bella , Rana, Adam J. , Sullivan, Nancy , Turgunbaev, Marat, Wysham, Katherine D. , Yip, Kevin , Yue, Linda, Zywiel, Michael G. , Russell, Linda , Turner, Amy S. , Goodman, Susan M , Baker, Joshua F , Bekele, Delamo , Ghomrawi, Hassan M K , Kwoh, Chian Kent , Bedard, Nicholas A. , Ghosh, Nilasha , King, Lauren K , Meara, Alexa Simon , Wysham, Katherine D , Turner, Amy S , Hannon, Charles P. , Austin, Matthew S. , Guyatt, Gordon , Aggarwal, Vinay Kumar , Dass, Danielle, Ghomrawi, Hassan , Lajam, Claudette M. , Meng, Charis F. , Moreland, Larry W. , Blevins, Jason L. , Fernandez‐Ruiz, Ruth , Gausden, Elizabeth B. , Mirza, Reza Donald , Singh, Jasvinder A.

Mayo Clinic

Arthritis Care & Research | September 25, 2023 | Volume: 75 | Issue: 11 | Pages: 2227-2238

10.1002/acr.25175 | PMID 37743767 Get It

ObjectiveTo develop evidence‐based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient‐important outcomes including, but not limited to, pain, function, infection, hospitalization, and death at 1 year for patients with symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis of the hip or knee who have previously attempted nonoperative therapy, and for whom nonoperative therapy was ineffective, and who have chosen to undergo elective hip or knee arthroplasty (collectively referred to as TJA).MethodsWe developed 13 clinically relevant population, intervention, comparator, outcomes (PICO) questions. After a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the quality of evidence (high, moderate, low, or very low), and evidence tables were created. A Voting Panel, including 13 physicians and patients, discussed the PICO questions until consensus was achieved on the direction (for/against) and strength (strong/conditional) of the recommendations.ResultsThe panel conditionally recommended against delaying TJA to pursue additional nonoperative treatment including physical therapy, nonsteroidal antiinflammatory drugs, ambulatory aids, and intraarticular injections. It conditionally recommended delaying TJA for nicotine reduction or cessation. The panel conditionally recommended delay for better glycemic control for patients who have diabetes mellitus, although no specific measure or level was identified. There was consensus that obesity by itself was not a reason for delay, but that weight loss should be strongly encouraged, and the increase in operative risk should be discussed. The panel conditionally recommended against delay in patients who have severe deformity or bone loss, or in patients who have a neuropathic joint. Evidence for all recommendations was graded as low or very low quality.ConclusionThis guideline provides evidence‐based recommendations regarding the optimal timing of TJA in patients who have symptomatic and radiographic moderate‐to‐severe osteoarthritis or advanced symptomatic osteonecrosis with secondary arthritis for whom nonoperative therapy was ineffective to improve patient‐important outcomes, including pain, function, infection, hospitalization, and death at 1 year. We acknowledge that the evidence is of low quality primarily due to indirectness and hope future research will allow for further refinement of the recommendations.
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
Badawi, Mohamed , Coppola, Sheryl , Eckert, Doerthe , Gopalakrishnan, Sathej , Engelhardt, Benjamin , Doelger, Eva, Dobkowska, Edyta, Kumar, Shaji , Menon, Rajeev , Menon, Rajeev M , Salem, Ahmed Hamed , Huang, Weize , Salem, Ahmed Hamed

Mayo Clinic

Hematological Oncology | September 23, 2023 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/hon.3222 | PMID 37740931 Get It

Abstract Venetoclax, a potent BCL‐2 inhibitor, is currently under development for treatment of t(11;14) Multiple myeloma (MM). The objective of this research was to investigate the exposure–response relationships of venetoclax for a phase 1/2 study evaluating venetoclax monotherapy or in combination with dexamethasone in relapsed or refractory MM. A total of 117 patients receiving venetoclax at 300, 600, 800, 900, or 1200 mg were included in the analysis. The impact of venetoclax exposures on efficacy (objective response rate [ORR], progression‐free survival [PFS] and overall survival [OS]) as well as safety (treatment‐emergent adverse effects (grade ≥3) of neutropenia, infection, and any grade of serious treatment‐emergent adverse effects) was evaluated. In the t(11;14)‐positive subpopulation, venetoclax exposure relationships to PFS and OS indicated a trend of longer PFS and OS with higher exposures. Moreover, logistic regression analyses for clinical response (ORR and ≥VGPR rate) demonstrated a statistically significant ( p < 0.05) relationship with exposure. Evaluation of the exposure‐safety relationships demonstrated a lack of a relationship between venetoclax exposures (AUC avg ) and grade ≥3 infections, grade ≥3 neutropenia, grade ≥3 treatment‐emergent adverse events or any grade serious treatment‐emergent adverse events. These findings support further study of venetoclax at 800 mg QD dose in combination with dexamethasone in the t(11;14)‐positive patient population where increased efficacy was observed without an increase in safety events.Clinical Trial: NCT01794520 registered 20 February 2013.
Recommendations for Centers Performing Pediatric Heart Surgery in the United States
Backer, Carl L., Overman, David M. , Romano, Jennifer C., Tweddell, James S., Marino, Bradley S. , Bacha, Emile , Jaquiss, Robert, Zaidi, Ali N. , Gurvitz, Michelle , Costello, John M. , Pierick, Trudy A. , Ravekes, William, Reagor, James A. , Spaeth, James P., Mahle, William T. , Shin, Andrew Y. , Karamlou, Tara , Welke, Karl F. , Bryant, Roosevelt , Husain, S. Adil , Chen, Jonathan M., Wells, Winfield J., Glatz, Andrew C. , McElhinney, Doff B. , Parra, David , Pasquali, Sara K. , McElhinney, Doff B , Dearani, Joseph A. , Kumar, S. Ram , Jaquiss, Robert D.B. , Louis, James D. St. , Lopez, Keila N. , Kaza, Aditya K.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | September 22, 2023 | Volume: 14 | Issue: 5 | Pages: 642-679

10.1177/21501351231190353 | PMID 37737602 Get It

Care and outcomes for the more than 40,000 patients undergoing pediatric and congenital heart surgery in the United States annually are known to vary widely. While consensus recommendations have been published across numerous fields as one mechanism to promote a high level of care delivery across centers, it has been more than two decades since the last pediatric heart surgery recommendations were published in the United States. More recent guidance is lacking, and collaborative efforts involving the many disciplines engaged in caring for these children have not been undertaken to date. The present initiative brings together professional societies spanning numerous care domains and congenital cardiac surgeons, pediatric cardiologists, nursing, and other healthcare professionals from diverse programs around the country to develop consensus recommendations for United States centers. The focus of this initial work is on pediatric heart surgery, and it is recommended that future efforts focus in detail on the adult congenital population. We describe the background, rationale, and methodology related to this collaborative effort, and recommendations put forth for Essential Care Centers (essential services necessary for any program), and Comprehensive Care Centers (services to optimize comprehensive and high-complexity care), encompassing structure, process, and outcome metrics across 14 domains.